Dheeraj Gandhi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dheeraj Gandhi has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Ajay Malhotra
Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT 06520, USA
19 shared publications - Dhairya A. Lakhani
Department of Neuroradiology, Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV 26506, USA
16 shared publications - Marco Colasurdo
Department of Interventional Radiology (M.C.), Oregon Health and Science University, Portland
15 shared publications - Huanwen Chen
Department of Neurosurgery, University of Maryland School of Medicine, Baltimore, MD 21201, USA
9 shared publications - Seyedmehdi Payabvash
Department of Radiology, Columbia University Irving Medical Center, New York, NY 10032, USA
7 shared publications - Adam Andrew Dmytriw
Nuffield Department of Surgical Sciences, Medical Sciences Division, University of Oxford, Oxford, United Kingdom
6 shared publications
Latest Publications
- Open Access
- 10 November 2026
- Published by MDPI AG in Diagnostics
- Vol. 16  (22) , 3710
Intravascular Optical Coherence Tomography for Neuroendovascular Intervention: Applications, Devices, and Future Directions
Background/Objectives: Intravascular optical coherence tomography (OCT) is a near-infrared light-based imaging modality with an axial resolution approaching 10 µm, roughly tenfold finer than intravascular ultrasound. Although OCT is established in coronary practice, its use in the cerebral circulation has been limited by catheter crossing profile, vessel tortuosity, and the need to clear blood from the vascular lumen during acquisition. In this narrative review, we summarize the physical principles of OCT, its plaque-characterization criteria and their histologic validation, the coronary evidence base, the imaging hardware available for intracranial use, and the reported clinical applications across intracranial atherosclerotic disease, intracranial aneurysms treated with flow diverters, carotid disease and carotid webs, arterial dissection, and venous and thromboembolic disease. We also discuss the technical barriers that limit routine neuroendovascular use. Methods: MEDLINE and PubMed were searched from inception through 1 September 2026 for English-language reports of intravascular OCT in human or animal cervical and intracranial vessels; study selection was not systematic. Results: The evidence base is composed largely of preclinical models, small human feasibility series, and case reports; no randomized or large-scale clinical outcome data exist. OCT has been feasible in selected cerebrovascular series, but the pooled evidence comes largely from extracranial carotid studies and does not establish its performance in intracranial vessels. Dedicated neurovascular probes have recently entered clinical study. In the coronary circulation, randomized evidence supports intravascular imaging-guided stent implantation and OCT-defined plaque features are associated with events; corresponding benefits have not been established intracranially. Conclusions: Intravascular OCT resolves the cerebral arterial wall and endoluminal devices in detail, but its safety and clinical benefit in neuroendovascular practice require further study. Prospective studies are needed to determine whether OCT findings change management and improve patient outcomes.
- 10 November 2026
- Published by MDPI AG in Diagnostics
- Vol. 16  (22) , 3710
Open AccessIntravascular Optical Coherence Tomography for Neuroendovascular Intervention: Applications, Devices, and Future Directions
Background/Objectives: Intravascular optical coherence tomography (OCT) is a near-infrared light-based imaging modality with an axial resolution approaching 10 µm, roughly tenfold finer than intravascular ultrasound. Although OCT is established in coronary practice, its use in the cerebral circulation has been limited by catheter crossing profile, vessel tortuosity, and the need to clear blood from the vascular lumen during acquisition. In this narrative review, we summarize the physical principles of OCT, its plaque-characterization criteria and their histologic validation, the coronary evidence base, the imaging hardware available for intracranial use, and the reported clinical applications across intracranial atherosclerotic disease, intracranial aneurysms treated with flow diverters, carotid disease and carotid webs, arterial dissection, and venous and thromboembolic disease. We also discuss the technical barriers that limit routine neuroendovascular use. Methods: MEDLINE and PubMed were searched from inception through 1 September 2026 for English-language reports of intravascular OCT in human or animal cervical and intracranial vessels; study selection was not systematic. Results: The evidence base is composed largely of preclinical models, small human feasibility series, and case reports; no randomized or large-scale clinical outcome data exist. OCT has been feasible in selected cerebrovascular series, but the pooled evidence comes largely from extracranial carotid studies and does not establish its performance in intracranial vessels. Dedicated neurovascular probes have recently entered clinical study. In the coronary circulation, randomized evidence supports intravascular imaging-guided stent implantation and OCT-defined plaque features are associated with events; corresponding benefits have not been established intracranially. Conclusions: Intravascular OCT resolves the cerebral arterial wall and endoluminal devices in detail, but its safety and clinical benefit in neuroendovascular practice require further study. Prospective studies are needed to determine whether OCT findings change management and improve patient outcomes.
- 14 August 2026
- Published by Wolters Kluwer Health in Neurosurgery
Glucagon-Like Peptide-1 Receptor Agonists for Patients with Conservatively Managed Nontraumatic Subdural Hematoma
BACKGROUND AND OBJECTIVES: Medical management options for nontraumatic subdural hematoma (SDH) remain limited, with only atorvastatin demonstrating benefit in a single phase 2 randomized clinical trial and mixed evidence for dexamethasone. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may benefit SDH outcomes. The objective of this study was to evaluate the association between GLP-1 RA use and rescue surgery rates and mortality in patients with medically managed nontraumatic SDH. METHODS: We conducted a retrospective cohort study using the TriNetX database from 2016 to 2025, including adults with SDH who were managed conservatively without surgical evacuation or middle meningeal artery embolization. Patients prescribed GLP-1 RAs were compared with nonusers. After propensity matching, rescue surgical evacuation, all-cause mortality at 1 year, and GLP-1 RA–associated adverse events were analyzed. RESULTS: A total of 134 901 patients with conservatively managed nontraumatic SDH were identified, of whom 1470 (1.1%) were GLP-1 RA users. After propensity score matching, 2922 patients remained, with 1461 in each group. At 1 year, GLP-1 RA users experienced significantly lower rates of rescue surgery (2.23% vs 3.51%; P = .046), culminating in an overall 38% reduction in relative hazard. All-cause mortality was also significantly lower for GLP-1 RA users at 1 year (16.1% vs 23.7%, P < .001), reflecting a 33% reduction in hazards. GLP-1 RA users did not experience different rates of adverse events, such as pancreatitis, gallbladder disease, or ileus/bowel obstruction (all P > .05). CONCLUSION: Among patients with medically managed nontraumatic SDH, GLP-1 RA use was associated with significantly lower rates of rescue surgery and all-cause mortality without significantly increased risk of common GLP-1 RA–related complications.
- 14 August 2026
- Published by Wolters Kluwer Health in Neurosurgery
Glucagon-Like Peptide-1 Receptor Agonists for Patients with Conservatively Managed Nontraumatic Subdural Hematoma
BACKGROUND AND OBJECTIVES: Medical management options for nontraumatic subdural hematoma (SDH) remain limited, with only atorvastatin demonstrating benefit in a single phase 2 randomized clinical trial and mixed evidence for dexamethasone. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may benefit SDH outcomes. The objective of this study was to evaluate the association between GLP-1 RA use and rescue surgery rates and mortality in patients with medically managed nontraumatic SDH. METHODS: We conducted a retrospective cohort study using the TriNetX database from 2016 to 2025, including adults with SDH who were managed conservatively without surgical evacuation or middle meningeal artery embolization. Patients prescribed GLP-1 RAs were compared with nonusers. After propensity matching, rescue surgical evacuation, all-cause mortality at 1 year, and GLP-1 RA–associated adverse events were analyzed. RESULTS: A total of 134 901 patients with conservatively managed nontraumatic SDH were identified, of whom 1470 (1.1%) were GLP-1 RA users. After propensity score matching, 2922 patients remained, with 1461 in each group. At 1 year, GLP-1 RA users experienced significantly lower rates of rescue surgery (2.23% vs 3.51%; P = .046), culminating in an overall 38% reduction in relative hazard. All-cause mortality was also significantly lower for GLP-1 RA users at 1 year (16.1% vs 23.7%, P < .001), reflecting a 33% reduction in hazards. GLP-1 RA users did not experience different rates of adverse events, such as pancreatitis, gallbladder disease, or ileus/bowel obstruction (all P > .05). CONCLUSION: Among patients with medically managed nontraumatic SDH, GLP-1 RA use was associated with significantly lower rates of rescue surgery and all-cause mortality without significantly increased risk of common GLP-1 RA–related complications.
- 13 August 2026
- Published by Wolters Kluwer Health in Neurosurgery
Carotid Artery Stenting Versus Carotid Endarterectomy for Asymptomatic Carotid Stenosis: A Propensity Score–Matched Real-World Analysis
BACKGROUND AND OBJECTIVES: Carotid artery stenting (CAS) and carotid endarterectomy (CEA) are established revascularization strategies for carotid stenosis, yet evidence comparing them in asymptomatic populations remains limited. The Carotid Revascularization Endarterectomy versus Stenting Trial-2 used a parallel-arm design and did not provide a direct head-to-head comparison of CAS vs CEA. This study evaluates real-world long-term outcomes of CAS compared directly with those of CEA in asymptomatic carotid stenosis. METHODS: Adults with asymptomatic carotid stenosis undergoing CAS or CEA between January 2016 and December 2024 were identified from the TriNetX US Collaborative Network. Patients with previous ischemic stroke, TIA, hemorrhage, or posterior-circulation stenosis were excluded. Propensity score matching (1:1) on demographics, comorbidities, and baseline antithrombotic medications yielded 5415 patients per cohort. Primary outcomes were all-cause mortality and ischemic stroke at 5 years; secondary outcomes included intraparenchymal hemorrhage and major bleeding. Kaplan–Meier analyses with log-rank testing and Cox proportional hazards models were used, with outcomes assessed at 6 months, 1, 3, and 5 years. RESULTS: Ischemic stroke occurred in 10.0% of CAS vs 9.8% of CEA patients (cumulative probability 15.85% vs 14.07%; hazard ratio [HR] 1.179, 95% CI 1.045-1.329, P = .007). All-cause mortality was higher after CAS (21.70% vs 18.69%; HR 1.212, 95% CI 1.084-1.355, P = .001). Intraparenchymal hemorrhage was more frequent after CAS (2.11% vs 1.30%; HR 1.940, 95% CI 1.327-2.835, P < .001). Major bleeding rates were comparable (12.10% vs 11.88%; HR 1.130, P = .071). All standardized differences were <0.10 postmatching. CONCLUSION: In real-world practice, CAS for asymptomatic carotid stenosis was associated with modestly higher ischemic stroke, mortality, and intraparenchymal hemorrhage compared with CEA over 5 years, suggesting an association favoring CEA. Prospective studies are needed to establish definitive causal relationships.
- 13 August 2026
- Published by Wolters Kluwer Health in Neurosurgery
Carotid Artery Stenting Versus Carotid Endarterectomy for Asymptomatic Carotid Stenosis: A Propensity Score–Matched Real-World Analysis
BACKGROUND AND OBJECTIVES: Carotid artery stenting (CAS) and carotid endarterectomy (CEA) are established revascularization strategies for carotid stenosis, yet evidence comparing them in asymptomatic populations remains limited. The Carotid Revascularization Endarterectomy versus Stenting Trial-2 used a parallel-arm design and did not provide a direct head-to-head comparison of CAS vs CEA. This study evaluates real-world long-term outcomes of CAS compared directly with those of CEA in asymptomatic carotid stenosis. METHODS: Adults with asymptomatic carotid stenosis undergoing CAS or CEA between January 2016 and December 2024 were identified from the TriNetX US Collaborative Network. Patients with previous ischemic stroke, TIA, hemorrhage, or posterior-circulation stenosis were excluded. Propensity score matching (1:1) on demographics, comorbidities, and baseline antithrombotic medications yielded 5415 patients per cohort. Primary outcomes were all-cause mortality and ischemic stroke at 5 years; secondary outcomes included intraparenchymal hemorrhage and major bleeding. Kaplan–Meier analyses with log-rank testing and Cox proportional hazards models were used, with outcomes assessed at 6 months, 1, 3, and 5 years. RESULTS: Ischemic stroke occurred in 10.0% of CAS vs 9.8% of CEA patients (cumulative probability 15.85% vs 14.07%; hazard ratio [HR] 1.179, 95% CI 1.045-1.329, P = .007). All-cause mortality was higher after CAS (21.70% vs 18.69%; HR 1.212, 95% CI 1.084-1.355, P = .001). Intraparenchymal hemorrhage was more frequent after CAS (2.11% vs 1.30%; HR 1.940, 95% CI 1.327-2.835, P < .001). Major bleeding rates were comparable (12.10% vs 11.88%; HR 1.130, P = .071). All standardized differences were <0.10 postmatching. CONCLUSION: In real-world practice, CAS for asymptomatic carotid stenosis was associated with modestly higher ischemic stroke, mortality, and intraparenchymal hemorrhage compared with CEA over 5 years, suggesting an association favoring CEA. Prospective studies are needed to establish definitive causal relationships.
- 22 July 2026
- Published by Elsevier in Journal of the American College of Radiology
- Vol. 23  (10) , 1995-1998
Medicare Graduate Medical Education Funding and Radiology Residency Growth: Trends and Implications for Workforce Policy
- 22 July 2026
- Published by Elsevier in Journal of the American College of Radiology
- Vol. 23  (10) , 1995-1998
Medicare Graduate Medical Education Funding and Radiology Residency Growth: Trends and Implications for Workforce Policy
- 17 July 2026
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 489, 126106
Association between glucagon-like peptide-1 receptor agonist use and ischemic stroke severity
- 17 July 2026
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 489, 126106
Association between glucagon-like peptide-1 receptor agonist use and ischemic stroke severity
- 26 June 2026
- Published by Elsevier in Respiratory Medicine
- Vol. 261, 109001
GLP-1 receptor agonists in obstructive sleep apnea: A propensity score-matched real-world analysis
- 26 June 2026
- Published by Elsevier in Respiratory Medicine
- Vol. 261, 109001
GLP-1 receptor agonists in obstructive sleep apnea: A propensity score-matched real-world analysis
- 30 May 2026
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 151, 112089
GLP-1 receptor agonists and post-endovascular thrombectomy outcomes in acute ischemic stroke: a multicenter propensity score matched analysis
- 30 May 2026
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 151, 112089
GLP-1 receptor agonists and post-endovascular thrombectomy outcomes in acute ischemic stroke: a multicenter propensity score matched analysis
- 30 May 2026
- Published by Elsevier in Academic Radiology
- Vol. 33  (8) , 3148-3155
International Medical Graduates in the U.S. Radiologist Workforce Characteristics: Perspectives from Medicare Administrative and Claims Datasets
- 30 May 2026
- Published by Elsevier in Academic Radiology
- Vol. 33  (8) , 3148-3155
International Medical Graduates in the U.S. Radiologist Workforce Characteristics: Perspectives from Medicare Administrative and Claims Datasets
- Open Access
- 21 May 2026
- Published by MDPI AG in Neurology International
- Vol. 18  (5) , 98
Association of Glucagon-like Peptide-1 Receptor Agonist Use with Stroke and Mortality Outcomes in Asymptomatic Intracranial Atherosclerotic Disease: Propensity Score-Matched Real-World Analysis
Background: Asymptomatic intracranial atherosclerotic arterial stenosis (ICAS) is an underrecognized entity for which vascular risk-factor optimization is the primary management strategy, with no current indication for routine antiplatelet therapy or endovascular intervention for primary stroke prevention. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce major adverse cardiovascular events, including stroke, in high-risk cardiometabolic populations, but their association with outcomes in asymptomatic ICAS is yet to be evaluated. The present study aims to evaluate the association between GLP-1RA use and cerebrovascular outcomes in adults with asymptomatic ICAS. Materials and Methods: We used the TriNetX US Collaborative Network (71 healthcare organizations) to identify adults (≥18 years) with ICAS between 1 January 2016 and 31 December 2025, and excluded patients with prior cerebral infarction, intracranial hemorrhage, or cerebrovascular ischemic syndromes. Exposure was defined as initiation of any GLP-1 receptor agonist (lixisenatide, semaglutide, liraglutide, tirzepatide, dulaglutide) during the 6 months before or on the date of index ICAS diagnosis. Outcomes were assessed at 1 year, and included ischemic stroke, all-cause mortality, and a composite of ischemic stroke or mortality. Propensity-score matching (1:1) was performed, including demographics, vascular risk factors, comorbidities, antithrombotics, lipid/diabetes therapies, and cardiometabolic laboratory/physiologic measures. Results: Before matching, 1746 GLP-1RA users and 71,792 non-users met inclusion criteria; after matching, 1728 patients remained in each cohort. GLP-1RA use was associated with lower 1-year risk of ischemic stroke (4.40% vs. 6.10%; hazard ratio [HR] 0.70, 95% CI 0.52–0.95; p = 0.044), lower all-cause mortality (3.40% vs. 9.40%; HR 0.35, 95% CI 0.26–0.47; p < 0.001), and lower composite outcome risk (7.50% vs. 15.00%; HR 0.48, 95% CI 0.39–0.59; p < 0.001). Notably, these associations were observed despite matching for HbA1c, LDL cholesterol, BMI, and systolic blood pressure, suggesting potential effects beyond measured cardiometabolic risk profiles. Conclusions: In this large, propensity-matched cohort of adults with a-ICAS, GLP-1RA use was associated with lower ischemic stroke, all-cause mortality, and composite outcome at 1 year. These findings are hypothesis-generating and require further prospective studies to confirm this observation.
- 21 May 2026
- Published by MDPI AG in Neurology International
- Vol. 18  (5) , 98
Open AccessAssociation of Glucagon-like Peptide-1 Receptor Agonist Use with Stroke and Mortality Outcomes in Asymptomatic Intracranial Atherosclerotic Disease: Propensity Score-Matched Real-World Analysis
Background: Asymptomatic intracranial atherosclerotic arterial stenosis (ICAS) is an underrecognized entity for which vascular risk-factor optimization is the primary management strategy, with no current indication for routine antiplatelet therapy or endovascular intervention for primary stroke prevention. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce major adverse cardiovascular events, including stroke, in high-risk cardiometabolic populations, but their association with outcomes in asymptomatic ICAS is yet to be evaluated. The present study aims to evaluate the association between GLP-1RA use and cerebrovascular outcomes in adults with asymptomatic ICAS. Materials and Methods: We used the TriNetX US Collaborative Network (71 healthcare organizations) to identify adults (≥18 years) with ICAS between 1 January 2016 and 31 December 2025, and excluded patients with prior cerebral infarction, intracranial hemorrhage, or cerebrovascular ischemic syndromes. Exposure was defined as initiation of any GLP-1 receptor agonist (lixisenatide, semaglutide, liraglutide, tirzepatide, dulaglutide) during the 6 months before or on the date of index ICAS diagnosis. Outcomes were assessed at 1 year, and included ischemic stroke, all-cause mortality, and a composite of ischemic stroke or mortality. Propensity-score matching (1:1) was performed, including demographics, vascular risk factors, comorbidities, antithrombotics, lipid/diabetes therapies, and cardiometabolic laboratory/physiologic measures. Results: Before matching, 1746 GLP-1RA users and 71,792 non-users met inclusion criteria; after matching, 1728 patients remained in each cohort. GLP-1RA use was associated with lower 1-year risk of ischemic stroke (4.40% vs. 6.10%; hazard ratio [HR] 0.70, 95% CI 0.52–0.95; p = 0.044), lower all-cause mortality (3.40% vs. 9.40%; HR 0.35, 95% CI 0.26–0.47; p < 0.001), and lower composite outcome risk (7.50% vs. 15.00%; HR 0.48, 95% CI 0.39–0.59; p < 0.001). Notably, these associations were observed despite matching for HbA1c, LDL cholesterol, BMI, and systolic blood pressure, suggesting potential effects beyond measured cardiometabolic risk profiles. Conclusions: In this large, propensity-matched cohort of adults with a-ICAS, GLP-1RA use was associated with lower ischemic stroke, all-cause mortality, and composite outcome at 1 year. These findings are hypothesis-generating and require further prospective studies to confirm this observation.